key: cord-1037809-zasihlev
authors: Ouyang, Yabo; Yin, Jiming; Wang, Wenjing; Shi, Hongbo; Shi, Ying; Xu, Bin; Qiao, Luxin; Feng, Yingmei; Pang, Lijun; Wei, Feili; Guo, Xianghua; Jin, Ronghua; Chen, Dexi
title: Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients
date: 2020-04-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa462
sha: 578f0cc202024ce9fdee39e4ddac118d8ec32d4b
doc_id: 1037809
cord_uid: zasihlev

BACKGROUND: WHO characterizes novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a pandemic. Here, we investigated the clinical, cytokine levels, T cell proportion and related gene expression occurring in COVID-19 patients on admission and after intial treatment. METHODS: 11 patients diagnosed as COVID-19 with similar initial treatment regimen were enrolled in the hospital. Plasma cytokines, CyTOF and microfluidic qPCR for gene expression were conducted. RESULTS: 5 mild and 6 severe patients were included. Cough and fever were the top symptoms in the 11 COVID-2019 cases. The elder age, more neutrophils numbers and higher C-reactive protein level were found in severe cases. IL-10 level was significantly varied with disease progression and treatment. The decreased T cell proportions were observed in COVID-19 patients especially in severe cases, and all elevated to normal in mild patiens after initial treatment but only CD4+T cells return to normal in severe cases. The number of DEGs increased with the disease progress, and decreased after initial treatment. All down-regulated DEGs in severe cases mainly involved in Th17 cell differentiation, cytokine-mediated signaling pathway and T cell activation. After initial treatmen in severe cases, MAP2K7 and SOS1 were upregulated relative to that on admission. CONCLUSIONS: Our findings show a decreased T cell proportion with down-regulated gene expression related to T cell activation and differentiation were occurred in COVID-19 severe patients, which may help to provide effective treatment strategies for COVID-19 .

The rapid outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have grown to be a global public health emergency of international concern since November 2019, which reported cases of COVID-19 around the world has surpassed 100,000 until March 07, 2020 [1] . The clinical characteristics of COVID-19 in China and the epidemiologic features of the outbreak in Wuhan and Hubei Province were reported which help identify the severity of the disease [2] [3] [4] [5] .

SARS-CoV-2, a member of Beta-CoV lineage B, was first identified in Wuhan, which can cause clusters of severe respiratory illness [6] . During viral infection, immune response were triggered by host against the virus. Many respiratory viruses suppress the innate immune response, providing opportunities for efficient virus replication and the establishment of infections [7] . The interaction of the virus with the cells results in a large number of immune mediators produced. In response to SARS-CoV-2 infection, infected cells promote the secretion of large amounts of chemokines and cytokines, which were reported in the COVID-19 severe cases [3] . Similar to Severe Acute Respiratory Syndrome (SARS) and

Middle East Respiratory Syndrome (MERS), the presence of "cytokine storm" may play a major role in pathogenesis, which cause inflammatory-induced lung injury and other complications [8] .

Beijing, the capital of China, a total of 428 COVID-19 patients were confirmed as of March 7, 2020 [9] . Our hospital, the specialized hospital for infectious diseases, providing the first line of confirming, diagnosing and treatment for COVID-19 patients. Despite several studies 

Patients and Clinical Samples: This study was approved by the ethics committee of Beijing YouAn Hospital. 11 patients diagnosed with COVID-19 with similar initial regimen were respectively enrolled from January 31 to February 07, 2020 in the hospital. All enrolled patients were confirmed to be positive for 2019-nCoV nucleic acid by real-time polymerase chain reaction. Patients were diagnosed and treated according to the guidance of National Health and Health Commission of China (version 7) and divided into two groups including severe or critically severe (group A) and mild or common (group B) type.

All the clinical data on demographics, symptoms, and laboratory results were retrospectively reviewed. Peripheral blood mononuclear cells (PBMCs) and the corresponding serum samples at admission (T1) and initial treatment with 5 days (T2) were collected for CyTOF, microfluidic qPCR and cytokine detection, respectivelly.

Each serum sample was analyzed for cytokines by Luminex bead based MILLIPLEX ® assay A c c e p t e d M a n u s c r i p t 6 using human cytokine panel a magnetic bead panel kit (Millipore, USA) with FlexMAP3D (Luminexs) platform and cytokine production data were analyzed using the xPONENT® software following the manufacturer's instructions [10] .

Total RNA was extracted from PBMCs using the RNeasy Plus Micro Kit (QIAGEN, Germany) according to the manufacturer's instructions. Quantity of total RNA was measured by Qubit (Thermofisher, USA). cDNAs were synthesized from and prepared with using the SuperScript® II first strand cDNA synthesis kit (Thermofisher, USA) according to the manufacturer protocol.

cDNA purification and dilution according to the instructions as described by Fluidigm (Fluidigm, USA) using probe-based TaqMan assays use primers to detect sequence-specific cDNA probes. 108 specific target genes were showed in supplementary Table S1 . Briefly, the gene expression assay with the GE 96.96 IFC using the Juno™ system for IFC preparation and Biomark HD for qPCR thermal cycling and data acquisition. Each value obtained is an average of two independent biological replicates, and the experiment was repeated two times for some genes as a batch effect correction. As described before, the GAPDH gene expression levels were used for data standardization, and the average gene expression level of 7 normal PBMC were used as the sample reference. The fold change was calculated using 2 −ΔΔCt method.

Differentially expressed genes (DEGs) were obtained using MeV tool, through compare the A c c e p t e d M a n u s c r i p t 7 fold change between NC group and group A or group B using Mann-Whitney Test with the statistical significance (two-side P value < 0.05), further DEG were hierarchical clustered in the software. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of differentially expressed genes was implemented on the metascape [11] . Identified GO terms and KEGG pathways with a corrected p < 0.05 were considered significantly enriched. Protein-protein interaction (PPI) analysis of DEGs was based on tissue specific PPI data from the DifferentialNet database, and the images were examined using NetworkAnalyst platform [12] .

All samples were incubated with cisplatin (195-Pt) and then quenched with CSB (Fluidigm) for viability evaluation by mass cytometry. A CD45 barcode was applied to minimize inter-sample staining variation, and stained with CD45 100 antibodies labeled with different metals before pooled together. The original FCS data were normalized and these files of each run were collected, then analyze with R and PhenoGraph.Statistical analysis:

Comparisons of differences between group A and group B were calculated using Mann-Whitney, Chi-Square or Fisher's exact test. Statistical significance was set at P value < 0.05 and for two-sided tests. Correlation analyses were performed using a Spearman's rank test. All statistical analyses were performed using the SPSS software package (version 17. Table 1 . In the basic characteristics, the median age of group A (67y) were significantly elder than group B (45y, P=0.043). The gender, occupation, source of infection, symptom and with chronic medical illness showed no significant difference between group A and group B. Overall, the top symptoms in the 11 COVID-2019 patients are cough (9/11, 81.82%) and fever (8/11, 72 .73%).

In the blood laboratory findings, we noticed that most of the results were not significantly different between the two groups except neutrophils number, albumin and C-reactive protein level. A more neutrophils numbers (median, 6.135 Vs 2.34, P=0.045) and higher C-reactive protein level (median, 78.3 Vs 13.7, P=0.006) were found in group A than that in group B.

While a relative lower level of albumin were more prone to observed in group A (median, 30.35 Vs 39.1, P=0.018). The blood laboratory results of all the patients except 2 patients from group B were compared within group, which showed no significantluy differences were found bewteen A1 and A2 or B1 and B2 after 5 days initinal treatment (Supplementary Table S2 ).

Plasma cytokines including IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ were evaluated that related to disease severity (A1 vs B1; A2 vs B2) and disease progress over time (A1 vs A c c e p t e d M a n u s c r i p t 9 A2; B1 vs B2) (Figure1A). It was indicated that IL-10 level were the only significantly different among A1 Vs B1 (P=0.020) and A1 and A2 group (P=0.050). Specifically, IL-10 level were higher in A1 (median:41.91 pg/mL, 20.23 -187.98 pg/mL) than that in B1 (median:14.40 pg/mL, 11.56 -18.47 pg/mL) on admission. After 5 days initial treatment, no significant difference were observed between A1 and A2 (median: 20.155 pg/mL, 14.71 -299.43 pg/mL) groups, while a decreased IL-10 level in B2 (median: 5.70 pg/mL, 3.00 -9.41 pg/mL) than B1 (median: 14.40 pg/mL, 11.56 -18.47 pg/mL) occurred. The potential correlation between IL-10 level of all COVID-19 cases and other cytokines or the corresponding immune cell counts were analyzed with the Spearman rank order correlation test ( Figure 1 and Supplementary FigureS1) . We found that the IL-10 level was positively correlated with IL-6 level ( Figure 1B 

We performed high-through qPCR to investigate the possible immune related 108 gene expression change in the 11 COVID-2019 patients. The DEGs of group A1 and group B1 relative to normal group at admission were analyzed. Comparisons between the two group were made with the Kruskal-Wallis test. The result showed A1_DEG number (63/108, 58.33% )were significantly greater than B1_DEG (39/108, 36.11%; P = 0.001). A total of 63 downregulated mRNA were differentially expressed in A1 group relative to NC group, while A c c e p t e d M a n u s c r i p t 10 in B1 group including 37 downregulated and 2 upregulated mRNA. These differentially expressed mRNAs were used for subsequent analysis. Cluster analysis of above DEGs was conducted with heat maps (Figures 2A) .

We performed an intersection analysis between the A1_DEG and B1_DEG. 34 genes were overlapped in the two groups, and 29 genes were specific to A1 group (Figures 2B) .

Enrichment Analysis were respectively performed on significantly differently expressed mRNAs in A1 vs NC and B1 vs NC. We found that both group A and group B DEGs enriched terms including such as Th17 cell differentiation, cytokine-mediated signaling pathway, sa mmp cytokine connection, natural killer cell mediated cytotoxicity and T cell activation Supplementary Table S3 and S4.

The tissue specific PPI data were collected from the DifferentiaNet database using NetworkAnalyst platform to screen the key genes involved in immune related genes of COVID-2019. According to the DEGs from the above two groups, the corresponding significant genes are mapped to the corresponding molecular interaction database ( Figure   2C ). The key genes with top degree (>20) and significantly FC (|log2 FC| > 1) involved in the A c c e p t e d M a n u s c r i p t 11 pathways interaction network were screened, which may play an import role in COVID-2019 ( Supplementary Table S4 and S5) . The FC of 14 key genes were significant differences among NC, A1 and B1 (all P<0.05, rank order: NC>B1>A1), and IL-2B, PIAS1, RPS6, HSPA8 and JUNB were both differences in A1 Vs NC and B1 Vs NC using the further multiple comparisons (adj P<0.05, Figure 2D ).

We then focused on the DEGs numbers in the two groups after initial treatment in the hospital.

It was displayed that the DEGs numbers of A2 (27/108, 25%) were significantly decreased than the patients at A1 (P=0.000). And the similar trend were found in group B2 (12/108, 11.11%, P=0.000). Heatmap showed the cluster analysis for the 27 and 12 DEGs for A2 and B2 group (Figures 3A) . All the DEGs from A2 and B2 were conducted KEGG enrichment analysis respectively. Th17 cell differentiation, Th1 and Th2 cell differentiation, Necroptosis, Jak-STAT signaling pathway, T cell receptor signaling pathway, TNF signaling pathway and MAPK signaling pathway were common significantly enriched terms both in A2 and B2 group (Figures 3B). Then we compared the differences and similarities between the two groups of patients at two time points. Specifically, 5 DEGs were common among the A1, B1, A2 and B2 groups (Figure 3C) , which including JUNB, NFATC3, JAK1, AHR and TNF were varied downregulated relative to NC group respectively though no regular difference among all the four groups ( Figure 3D, all P >0.05) .

Finally, we focus on the DEGs changed during group A1 and A2. It is observed that the FC of A c c e p t e d M a n u s c r i p t 12 14 key genes from Figure 2D that expressed on A2 group, which shown FC of 11 in 14 genes were significant differences among NC, A1 and A2 group, IL2B, RPS6, HSPA8, JUNB, PIAS1 were both down-regulated in A1 and A2 based on the following multiple comparisons ( Figure 4A, adj P<0.05) . The group A specific DEGs were defined according to get intersection DEGs of A1 and A2 but exclude B1, which showed 7 mRNA including CBL, PTPN6, LCK, PRKCQ, CEBPB, MAPK8 and PARP2 were considered as severe COVID-2019 specific DEGs (Figure 4B, all P<0 .05 among NC, A1 and A2 group) and PTPN6 were both down-regulated in A1 and A2 that relative to the NC group (adj P<0.05).

After initial treatment, It is showed that MAP2K7 and SOS1 of A2 were the only two significantly DEGs that upregulated relative to A1, which involved in T cell receptor signaling pathway and Fc epsilon RI signaling pathway that play important roles in disease progression through immune-related signaling pathways. (Figure 4C ) . Using CyTOF mass cytometry (Figure 4D) , we found A1 were significantly decreased in proportion of T cells 

The current outbreak of COVID-19 that was first reported from Wuhan and declared a Public Health Emergency of International Concern on 30 January 2020 by WHO. Based on the data A c c e p t e d M a n u s c r i p t 13 of 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in 30 provinces of China, the most common symptoms of COVID-19 are fever and cough, followed by other respiratory symptoms [2] . Similarly, in the present study, the top symptoms in the 11 COVID-2019 patients are cough (9/11, 81.82%) and fever (8/11, 72 .73%). Older people (group A) were prone to develop as severe stage. In terms of laboratory finding, more neutrophils numbers and higher C-reactive protein level were found in severe (group A) cases, which were consistent with other COVID-19 reports [4] [13] . After 5 days initinal treatment, no significantluy differences were found in blood laboratory results in either type of disease.

The immune system plays an important role in resisting respiratory viruses, and incomplete, delayed, weakened or strong immune response of the host may cause tissue damage [7] . It is reported that IL-2R, IL-6, IL-10, IP-10, MCP-1, MIP-1A, or TNFα increased in the majority of severe cases [3, 13] . We also found IL-10 was fluctuated vary in different COVID-19 progressions, which was the only difference between A1 and B1, A2 and B2 group respectively. Interestingly, After 5 days initial treatment, IL-10 in mild group (group B) was significantly dropped while still kept similar level in severe group (group A). The above results suggest the early high level of serum pro-inflammatory cytokines indicating a potentially cytokine storm-mediated disease severity, which was similar to SARS-CoV and MERS-CoV infections [14, 15] . Dysregulated immune response were occurred in COVID-19 patients [16] . IL-10 can be produced by most cells of the immune system, and suppresses the immune response by preventing various cell types from inhibiting the synthesis of a number of cytokines, including IFN-γ, IL-2, IL-3, IL-5, IL-6 , IL-8, IL-12, TNF and GM-CSF [17] .

The anti-inflammatory properties of IL-10 play a key role in determining the outcome of the A c c e p t e d M a n u s c r i p t 14 infection, which found the absence of IL-10 leads to better pathogen clearance [18] .

SARS-CoV-2 infection could affect the mRNA expression level related with immune functions in COVID-19 cases. Our study revealed the number of misregulated genes increased as the disease progressed when compared to normal. A more DEGs were found in severe cases. Both DEGs of severe and mild patients are participated in such as Th17 cell differentiation, cytokine-mediated signaling pathway, sa mmp cytokine connection, natural killer cell mediated cytotoxicity and T cell activation. While DEGs specific to severe cases were mainly responsible for CD8 TCR pathway, EPO pathway, signaling by Interleukins, TNF signaling pathway, entry into host cell and regulation of T cell proliferation enrichment terms. These results indicated SARS-CoV-2 infection may resulting inspecific Th1/Th17 inactivation and impaired inflammatory responses, which may related to the decreased proportion of T cells expecially in COVID-19 severe patients.. 14 key genes related with immune functions in COVID-19 cases were screened, which revealed FC down-regulated more in group A1 than that in group B1 both relative to the NC group. Like influenza viruses, CoVs such as SARS-CoV and MERS-CoV also use a combination of ways to achieve host shut-off both at the transcriptional and the translational levels [7] . Innate and adaptive immune responses to viral infection during infection. Coronaviruses (CoVs) infects macrophages and presents CoV antigens to T cells, which process could results in T cell activation and differentiation that including the production of cytokines associated with different T cell subpopulations, and subsequent large release of cytokines for immune response expansion [19] .However, in the severe COVID-19 patients before treatment we A c c e p t e d M a n u s c r i p t 15 oberved the opposite phenomenon with decreased T cell numbers and suppressed cytokines except IL-10.

Then we found the DEGs numbers in the two groups after initial treatment in the hospital were decreased than that on admission. The DEGs after initial treatment in COVID-19 cases both mainly enriched on Th1, Th2 and T17 cell differentiation, Jak-STAT signaling pathway, T cell receptor signaling pathway and TNF signaling pathway. Potential key genes related to COVID-2019 immune response were screened that involved in T cell activation and differentiation. After initial treatmen in severe cases, MAP2K7 and SOS1 were upregulated relative to that on admission, which involved in T cell receptor signaling pathway and Fc epsilon RI signaling pathway that play important roles in disease progression. MAP2K7

activates the c-Jun kinases JNK1 and JNK2 in response to T-cell activation signals, mediates T-cell gene expression programs and cytokine expression [20] . SOS1 significantly contributes to ERK activation during sustained TCR signaling and T-cell activation [21] . We also found after initial treatment, the CD4+ T cells of severe patients return to normal proportion, and a bit of improvement for CD8+T cells though still less than normal.Our study has some notable limitations. First, limited sample size with the similar initial regimen in the same period were entrolled in this study, which may limits the robustness of the conclusions. Secondly, 108 mRNA for gene expression detection were used in this study for the preliminary observed the Protein-protein interaction (PPI) network of DEGs of A1 and B1 group. PPI network was drawn using NetworkAnalyst platform based on tissue specific PPI data from the DifferentialNet database. The red circles represented the up-regulated genes, the green circles down-regulated genes and gray circles indicated·not included in DEGs. D. Kruskal-Wallis 1-way ANOVA was used to screen the 14 significant differences gene among NC, A1 and B1.

Then the multiple comparisons with all pairwise were performed. Statistical significance was set at a two-sided P < 0.05 and adj P< 0.05. *P<0.05;** P<0.01. 

World health organization. Coronavirus disease (covid-2019) situation reports-47

Clinical characteristics of coronavirus disease 2019 in china

Clinical features of patients infected with 2019 novel coronavirus in wuhan, china

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: a descriptive study

Clinical course and outcomes of critically ill patients with SARS-cov-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study

A novel coronavirus from patients with pneumonia in china

Innate immune evasion by human respiratory rna viruses

Immune responses in covid-19 and potential vaccines: lessons learned from SARS and mers epidemic

The people's government of beijing municipality, coronavirus disease (covid-2019) situation reports

A useful guide for analysis of immune markers by fluorochrome (luminex) technique

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

Networkanalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis

A new coronavirus associated with human respiratory disease in china

Mers-cov infection in humans is associated with a pro-inflammatory th1 and th17 cytokine profile

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Dysregulation of immune response in patients with covid-19 in wuhan, china

Suppressor of cytokine signaling 1 inhibits il-10-mediated immune responses

The regulation of il-10 production by immune cells

Coronavirus infections and immune responses

Widespread jnk-dependent alternative splicing induces a positive feedback loop through celf2-mediated regulation of mkk7 during t-cell activation

Sos1 regulates sustained tcr-mediated erk activation

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 20 A c c e p t e d M a n u s c r i p t